Attached files

file filename
10-K - UNIGENE LABORATORIES, INC. - UNIGENE LABORATORIES INCd10k.htm
EX-23.2 - CONSENT OF ERNST & YOUNG LLP - UNIGENE LABORATORIES INCdex232.htm
EX-23.1 - CONSENT OF GRANT THORNTON LLP - UNIGENE LABORATORIES INCdex231.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - UNIGENE LABORATORIES INCdex322.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - UNIGENE LABORATORIES INCdex311.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - UNIGENE LABORATORIES INCdex312.htm
EX-10.70 - COLLATERAL ASSIGNMENT AGREEMENT - UNIGENE LABORATORIES INCdex1070.htm
EX-10.67 - LICENSE AGREEMENT - UNIGENE LABORATORIES INCdex1067.htm
EX-10.71 - WARRANT EXCHANGE AGREEMENT - UNIGENE LABORATORIES INCdex1071.htm
EX-10.64 - ASSIGNMENT AND ASSUMPTION AGREEMENT - UNIGENE LABORATORIES INCdex1064.htm
EX-10.69 - OMNIBUS AMENDMENT AGREEMENT - UNIGENE LABORATORIES INCdex1069.htm
EX-10.68 - AMENDMENT TO LICENSE AGREEMENT - UNIGENE LABORATORIES INCdex1068.htm
EX-10.56 - ASSIGNMENT OF MORTGAGE - UNIGENE LABORATORIES INCdex1056.htm
EX-10.11 - FORM OF RESTRICTED AGREEMENT - UNIGENE LABORATORIES INCdex1011.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES OXLEY ACT OF 2002

In connection with the Annual Report of Unigene Laboratories, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Warren P. Levy, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial position and results of operations of the Company.

 

/s/ Warren P. Levy

Warren P. Levy
Chief Executive Officer
March 16, 2010

A signed original of this written statement required by Section 906 has been provided to Unigene Laboratories, Inc. and will be retained by Unigene Laboratories, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.